Literature DB >> 2506173

Domain II mutants of Pseudomonas exotoxin deficient in translocation.

Y Jinno1, M Ogata, V K Chaudhary, M C Willingham, S Adhya, D FitzGerald, I Pastan.   

Abstract

Pseudomonas exotoxin (PE) kills mammalian cells in a complex process that involves cell surface binding, internalization by endocytosis, translocation to the cytosol, and ADP-ribosylation of elongation factor 2. PE is a three-domain protein in which domain I binds to the cell surface, domain II promotes translocation into the cytosol, and domain III carries out ADP-ribosylation. To determine how translocation occurs, we have mutated all the arginine residues in domain II and found that mutations at positions 276 and 279 greatly diminished the cytotoxicity of PE and mutations 330 and 337 substantially reduced cytotoxicity. Biochemical studies indicate that after internalization into an endocytic compartment, the PE molecule undergoes a specific and saturable intracellular interaction, and this interaction is deficient in an Arg276----Gly mutant. Our data suggest that the translocation process of PE involves a specific interaction of Arg276 (and possibly Arg279, Arg330, and Arg337) with components of an intracellular compartment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506173

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  22 in total

1.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 2.  Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases.

Authors:  V M Gordon; S H Leppla
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease.

Authors:  Diane M Da Silva; Joseph G Skeate; Elena Chavez-Juan; Kim P Lühen; Jiun-Ming Wu; Chia-Mao Wu; W Martin Kast; KinKai Hwang
Journal:  Vaccine       Date:  2019-04-19       Impact factor: 3.641

4.  A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

Authors:  Seunguk Oh; Deborah A Todhunter; Angela Panoskaltsis-Mortari; Donald J Buchsbaum; Shoko Toma; Daniel A Vallera
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

5.  Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.

Authors:  Hetal Pandya; Waldemar Debinski
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

6.  Molecular targeting of intracellular compartments specifically in cancer cells.

Authors:  Hetal Pandya; Denise M Gibo; Waldemar Debinski
Journal:  Genes Cancer       Date:  2010-05

7.  Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice.

Authors:  U Brinkmann; L H Pai; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 12.779

8.  Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections.

Authors:  U Brinkmann; J Buchner; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 12.779

9.  Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes.

Authors:  M Ogata; I Pastan; D FitzGerald
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.609

10.  Characterization of a cellular protease that cleaves Pseudomonas exotoxin.

Authors:  C Fryling; M Ogata; D FitzGerald
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.